Market Access News | pharmaphorum

News

Japan approves two more COVID vaccines as fourth infection w...

Japan has approved two more coronavirus vaccines, while expanding a state of emergency to cover the southern island of Okinawa.

News

How-cell-and-gene-therapies-are-transforming-the-pace-of-deal-making

CHMP backs bluebird bio's gene therapy for rare disease ALD

US biotech bluebird bio has had a challenging time in the last few months, so a recommendation for EU approval of its gene therapy for adrenoleukodystrophy (ALD) will give it a lift.

News

NICE rejects J&J's prostate cancer drug Erleada in initial g...

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance.

News

Apellis set to take on Alexion as FDA clears PNH drug Empave...

Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal hemoglobinuria (PNH) – with a label that will allow it to challenge

News

NICE says final 'no' to BMS' Zeposia for multiple sclerosis

NICE has issued a final “no” to Bristol-Myers Squibb’s oral MS drug Zeposia (ozanimod), in a decision that prevents access for patients in England and Wales.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

UK government rethinks plans to buy AZ antibody doses - repo...

The UK government has got cold feet over plans to buy a million doses of AstraZeneca’s antibody treatment for coronavirus, according to a press report.

Japan approves two more COVID vaccines as fourth infection w...

CHMP backs bluebird bio's gene therapy for rare disease ALD

NICE rejects J&J's prostate cancer drug Erleada in initial g...

Apellis set to take on Alexion as FDA clears PNH drug Empave...

NICE says final 'no' to BMS' Zeposia for multiple sclerosis

UK government rethinks plans to buy AZ antibody doses - repo...

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

News

Editor's Picks